Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 6/20 | 0.36 |
| ▸ | APP | P05067 | 2/20 | 0.33 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.33 |
| ▸ | CTSD | P07339 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4599454 | 0.88 | BACE1 (0.47) | SLC6A2SLC6A4SLC6A3BACE1APP | |
| SCHEMBL4599783 | 0.87 | BACE1 (0.36) | SLC6A4SLC6A3BACE1APPBACE2 | |
| SCHEMBL4598536 | 0.84 | SLC6A4 (0.44) | SLC6A2SLC6A4SLC6A3BACE1 | |
| SCHEMBL2955293 | 0.82 | BACE1 (0.57) | BACE1 | |
| SCHEMBL5515650 | 0.82 | BACE1 (0.48) | SLC6A2SLC6A4SLC6A3BACE1APP | |
| SCHEMBL4599019 | 0.81 | POLB (0.37) | SLC6A2SLC6A4SLC6A3BACE1APP | |
| SCHEMBL7537531 | 0.80 | BACE1 (0.56) | BACE1 | |
| SCHEMBL4597602 | 0.80 | BACE1 (0.46) | SLC6A2SLC6A4SLC6A3BACE1APP | |
| SCHEMBL4598839 | 0.80 | BACE1 (0.36) | SLC6A2SLC6A4SLC6A3BACE1APP | |
| SCHEMBL5521710 | 0.79 | CHRM2 (0.40) | BACE1APPBACE2CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1910309-A2 | CYCLOALKYL AMINO-HYDANTOIN COMPOUNDS AND USE THEREOF FOR ß-SECRETASE MODULATION | Wyeth (US) | 2008-04-16 | — | — | EP | claimed |
| WO-2007016012-A2 | CYCLOALKYL AMINO-HYDANTOIN COMPOUNDS AND USE THEREOF FOR β-SECRETASE MODULATION | WYETH (US) | 2007-02-08 | — | — | WO | claimed |
| US-20070027199-A1 | Cycloalkyl amino-hydantoin compounds and use thereof for beta-secretase modulation | WYETH (US) | 2007-02-01 | — | — | US | claimed |
| US-20070027199-A1 | Cycloalkyl amino-hydantoin compounds and use thereof for beta-secretase modulation | WYETH (US) | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027199-A1 | Cycloalkyl amino-hydantoin compounds and use thereof for beta-secretase modulation | BACE1, BACE2, APP | SLC6A2 2887/4885SLC6A4 2587/4885SLC6A3 3233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.